Drug intelligence / Profile preview

MEDI-575 + carboplatin + paclitaxel

Development stage: Unknown
Lead developer: MedImmune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

MEDI-575 + carboplatin + paclitaxel is a combination therapy that was investigated for the treatment of advanced non-small cell lung cancer (NSCLC). MEDI-575 is a fully human monoclonal antibody that selectively binds to platelet-derived growth factor receptor alpha (PDGFRα) with high specificity. This combination was studied in a Phase 1b/2 clinical trial to evaluate its efficacy, safety, and pharmacology compared to carboplatin plus paclitaxel alone in previously untreated advanced NSCLC patients.

Targets

PDGFRA (Platelet-derived growth factor receptor alpha)

Beyond the preview

Go deeper on MEDI-575 + carboplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI-575 + carboplatin + paclitaxel.

Explore the full profile